BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Institute Curie Hospital Purchases Second TomoTherapy Radiation Therapy System


10/15/2009 12:30:56 PM

MADISON, WI--(Marketwire - October 15, 2009) - TomoTherapy Incorporated (NASDAQ: TOMO) announced today that the Institute Curie Hospital in France has purchased a second TomoTherapy® radiation therapy system, to support the increasing demand for intensity-modulated radiation therapy (IMRT). The Institute Curie Hospital has been treating cancer patients with TomoTherapy technology since March 2007, when it became the first hospital in France to adopt the technology. Now, with this most recent purchase, there are eight TomoTherapy systems in use in France to treat patients with routine, complex and rare cancers.

"We typically treat our most complex cases -- such as sarcomas, head and neck tumors with multiple treatment volumes, and lung, pancreatic and liver cancers -- with TomoTherapy," said Dr. Alain Fourquet, head of the Department of Radiation Oncology at the Institute Curie Hospital. "The addition of a second unit will allow us to increase our ability to care for more patients in need of advanced radiation therapy and enable us to expand the types of indications we can treat to include pelvic tumors and some complicated cases of breast cancer. In addition, we hope to use the second TomoTherapy system to assist us in conducting prospective clinical trials and research in physics projects."

The Institute Curie is a private foundation combining France's largest cancer research center and a leading edge hospital. It was founded in 1909 by Marie Curie with the primary purpose of defeating cancer, and it received state approval as a foundation in 1921. Internationally renowned for its work in the diagnosis and treatment of cancers, the Institute Curie serves as a reference center throughout the world on the implementation of innovative treatments.

The second TomoTherapy system at Institute Curie Hospital will replace an aging cobalt radiation machine. The small footprint of the TomoTherapy unit will enable the hospital to install the new technology while minimizing the need for extensive remodeling. The hospital decided to purchase its first TomoTherapy system after the National Cancer Institute called for research proposals to promote IMRT technology not previously available in France.

"The Institute Curie is among the most prestigious cancer research facilities in the world and is well known for its high standard of care," said Patrice Lompech, TomoTherapy sales manager in France. "The hospital's decision to expand its TomoTherapy practice is further validation of the platform's power for treating a wide variety of cases and demonstrates the confidence staff has in our platform, as they provide the highest quality 3D image-guided treatments for patients."

The Institute Curie will present three TomoTherapy treatment-related abstracts at the Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held November 1-5, 2009, in Chicago. The scientific papers highlight Institute Curie's research work involving uncommon and clinically challenging cases in plasmocytoma and extensive malignant lymphoma in conjunction with stem cell transplant, as well as preliminary studies on the use of TomoTherapy technology in breast cancer treatment.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2009 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.


Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
Email Contact

Media Contacts:
Kevin O'Malley
Manager, Corporate Communications
608.824.3384
Email Contact

Susan Lehman
Rockpoint Public Relations
510.832.6006
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES